ProductDescription
Vitronectinisamonomericglycoproteinusedtopromotecellattachment,migration,proliferationanddifferentiationinabroadnumberofcelllinesandtypes.Thisproducthasbeenpurifiedfromhumanplasmawhereitisfoundasamixtureof75kDaand65kDapolypeptides.
Vitronectin’sprimaryuseincellcultureisrelatedtocelladhesion.Italsobindstoheparinandcollagen.
Vitronectinisidealforcoatingofsurfaces.Theoptimalconcentrationforcellattachmentandculturemaydifferforvariouscelltypes.Vitronectinhasbeenusedatafinalcoatingconcentrationaslowas50ng/cm2onplasticware.Itisprovidedinuser-friendlypackagingforuseandstorage.Vitronectinissterilefilteredandissuppliedasareadytousesolutionafterthawingandconcentrationadjustment.Thisproductisshippedseparatelyondryice.
| Parameter,Testing,andMethod | Vitronectin#5051 |
| Quantity | 0.1mg |
| Volume | 0.2mL |
| Concentration | 0.5mg/mL |
| Purity-SDSPAGEElectrophoresis | >95% |
| Formulation | 0.15MNaCl,0.005MHEPESpH7.4 |
| Form | Solution |
| Source | Human,Plasma |
| StorageTemperature | -20°Cor-70°Cforlongtermstorage |
| ShelfLife | Minimumof6monthsfromdateofreceipt |
| SterilizationMethod | Filtration |
| CellAttachmentAssay | Passes |
| Sterility-USPmodified | Nogrowth |
| Safety | Sourcematerialfoundnegativeforinfectiousagents |
DirectionsforUse
DownloadthefullPDFversionorcontinuereADIngbelow:
CoatingProcedure:
Usetheserecommendationsasguidelinestodeterminetheoptimalcoatingconditionsforyourculturesystem.
- ThawVitronectinanddilutetodesiredconcentrationusingserum-freemediumorPBS.Thefinalsolutionshouldbesufficientlydilutesothatthevolumeaddedcoversthesurfaceevenly.
- Addappropriateamountofdilutedmaterialtoculturesurface.
- Incubateatroomtemperatureforapproximately1–2hours.
- Aspirateremainingmaterial.
- RinseplatescarefullywithdH2O–avoidscratchingbottomsurfaceofplates.
- Platesarereadyforuse.Theymayalsobestoredat2-8°Cdamporairdriedifsterilityismaintained.
ProductReferences
VitronectinReferences:
Wiley,LukeA.,etal."Usingpatient-specificinducedpluripotentstemcellsandwild-typemicetodevelopageneaugmentation-basedstrategytotreatCLN3-associatedretinaldegeneration."Humangenetherapy27.10(2016):835-846.
Wiley,LukeA.,etal."Generationofxeno‐free,cGMP‐compliantpatient‐specificiPSCsfromskinbiopsy."CurrentprotocolsinstemcellBIOLOGy42.1(2017):4A-12.
Dwyer,SheilaFigel,LingqiuGao,andIrwinH.Gelman."Identificationofnovelfocaladhesionkinasesubstrates:RoleforFAKinNFκBsignaling."Internationaljournalofbiologicalsciences11.4(2015):404.
Wiley,LukeA.,etal."cGMPproductionofpatient-specificiPSCsandphotoreceptorprecursorcellstotreatretinaldegenerativeblindness."Scientificreports6(2016):30742.
Kittur,Harsha,etal."ProbingCellAdhesionProfileswithaMicroscaleAdhesiveChoiceAssay."Biophysicaljournal113.8(2017):1858-1867.
Dwyer,SheilaFigel,andIrwinH.Gelman."Cross-phosphorylationandinteractionbetweenSrc/FAKandMAPKAP5/PRAKinearlyfocaladhesionscontrolscellmotility."Journalofcancerbiology&research2.1(2014).
Worthington,KristanS.,etal."Two-photonpolymerizationforproductionofhumaniPSC-derivedretinalcellgrafts."ActaBiomaterialia55(2017):385-395.
ProductCertificateofAnalysis
SafetyandDocumentation
SafetyDataSheet
CertificateofOrigin
ProductDisclaimer
ThisproductisforR&Duseonlyandisnotintendedforhumanorotheruses.PleaseconsulttheMaterialSafetyDataSheetforinformationregardinghazardsandsafehandlingpractices.

